Large Shionogi tumors lose their responsiveness to flutamide treatment

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 5-6, 1996, Pages 489-494

  Chen, Cailin ^a   Poulin, Richard ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; FLUTAMIDE;

ANIMAL; ARTICLE; CARCINOMA; CELL DIVISION; DRUG EFFECT; EXPERIMENTAL NEOPLASM; HUMAN; MALE; MOUSE; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; CELL DIVISION; FLUTAMIDE; HUMANS; MALE; MICE; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS;

EID: 0030203120     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00069-6     Document Type: Article

References (33)

1. Wingo P. A., Tong T. and Bolden S.: Cancer statistics, 1995. CA Cancer J. Clin. 45 (1995) 8-30.
2. Labrie F., Dupont A., Bélanger A., Cusan L., Lacourcière Y., Monfette G., Laberge J. G., Emond J., Fazekas A. T. A., Raynaud J. P. and Husson J. M.: New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. J. Clin. Invest. Med. 5 (1982) 267-275.
3. Labrie F., Dupont, A. and Bélanger, A.: Complete androgen blockade for the treatment of prostate cancer. In Important Advances in Oncology (Edited by V. T. de Vita, S. Hellman and S. A. Rosenberg). J.B. Lippincott, Philadelphia (1985) 193-217.
4. Crawford D., Eisenberger M. A., McLeod D. G., Spaulding J. T., Benson R., Dorr F. A., Blumenstein D. A., Davis M. A. and Goodman P. J.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl. J. Med. 321 (1989) 419-424.
5. Denis L., Carneiro de Moura J. L., Bono A., Sylvester R., Wheeton R., Newling D. and Pauno M. D.: Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42 (1993) 119-129.
6. Janknegt R. A., Abbou C. C., Bartoletti R., Bernstein-Hahn L., Bracken B., Brisset J. M., Silva F. C. D., Knonagel H. and Venner P.: Orchiectomy and Anandron (Nilutamide) or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J. Urology 149 (1993) 77-83.
7. Labrie F.: Endocrine therapy of prostate cancer: optimal form and timing. J. Clin. Endocrinol. Metab. 80 (1995) 1066-1071.
8. Labrie, F., Cusan, L., Gomez, J. L., Diamond, P. and Candas, B.: Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J. Clin. Endocr. Metab. (1995).
9. Dexter D. L. and Calabresi P.: Intraneoplastic diversity. Biochem. Biophys. Acta 695 (1982) 97-112.
10. Heppner G. H.: Tumor heterogeneity. Cancer Res. 44 (1984) 2259-2265.
11. Nicolson G. L.: Tumor cell instability, diversification, and progression to metastatic phenotype: from oncogene to oncofetal expression. Cancer Res. 47 (1987) 1473-1487.
12. Fearon E. R. and Vogelstein B.: A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767.
13. Nowell P. C.: The clonal evolution of tumor cell populations. Science 194 (1976) 23-28.
14. Scrable H. J., Sapienza C. and Cavenee W. K.: Genetic and epigenetic losses of heterozygosity in cancer predisposition and progression. Adv. Cancer Res. 54 (1990) 25-62.
15. Artega, C. L. and Osborne, C. K.: Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. In Regulatory Mechanisms in Breast Cancer (Edited by M. E. Lippman and R. B. Dickson). Kluwer Academic Press, Boston (1991) 289 pp.
16. MacIndoe J.: The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. Endocrinology 123 (1988) 1281-1287.
17. Minesita T. and Yamaguchi K.: An androgen-dependent tumor derived from a hormone-independent tumor of a female mouse. Steroids 4 (1964) 815-830.
18. Minesita T. and Yamaguchi K.: An androgen-dependent mouse mammary tumor. Cancer Res. 25 (1965) 1168-1175.
19. Labrie F. and Veilleux R.: A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. The Prostate 8 (1986) 293-300.
20. Labrie F., Veilleux R. and Fournier A.: Low androgen levels induce the development of androgen-hypersensitive cells clones in Shionogi mouse mammary carcinoma cells in culture. J. Natl. Cancer Inst. 80 (1988) 1138-1147.
21. Desmond W. J., Wolbers S. J. and Sato G.: Cloned mouse mammary cell lines requiring androgens for growth in culture. Cell 8 (1976) 79-86.
22. Suzuki T., Horibe I., Uchida N., Ezumi K., Uchida K., Tadeda K., Tanaka A., Nishizawa Y. and Matsumoto K.: Effects of antiandrogens on growth of androgen-dependent mouse mammary tumor (Shionogi Carcinoma 115) in vivo and in vitro. J. Steroid Biochem. Molec. Biol. 37 (1990) 559-567.
23. Noguchi S., Nishizawa Y., Motomura K., Inaji H., Imaoka S., Koyama H. and Matsumoto K.: Inhibitory effect of a somatostatin analogue (SMS 201-995) on the growth of androgen-dependent mouse mammary carcinoma (Shionogi carcinoma 115) cells in culture. Jpn J. Cancer Res. 84 (1993) 656-663.
24. Luthy I., Bégin D. and Labrie F.: Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J. Steroid Biochem. 31 (1988) 845-852.
25. Bradford M.: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem. 72 (1976) 248-254.
26. Kramer C. Y.: Extension of multiple range tests to group means with unique numbers of replications. Biometrics 12 (1956) 307-310.
27. Bullock L. P.: Androgen and progestin stimulation of ornithine decarboxylase activity in the mouse kidney. Endocrinology 112 (1983) 1903-1909.
28. Pajunen A. E. I., Isomaa V. V., Janne O. A. and Bardin C. W.: Androgenic regulation of ornithine decarboxylase activity in mouse kidney and its relationship to changes in cytosol and nuclear androgen receptor concentrations. J. Biol. Chem. 257 (1982) 8190-8198.
29. Katomura Y., Okamoto, S., Uchida, N., Yamaguchi, K. and Marsumoto, K.: Effect of androgen depletion on growth and androgen dependency of Shionogi carcinoma 115. Cancer Res. 38 (1978) 4711-4716.
30. Veterans Administration Cooperative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg. Gynecol. Obstet. 124 (1967) 1011-1017.
31. Eisenberger M. A., Crawford D. E., Wolf M., Blumenstein B., McLeod D. G., Benson R., Dorr F. A., Benson M. and Spaulding J. T.: Prognostic factors in stage D2 prostate cancer - Important implications for future trials - Results of a cooperative intergroup study. Semin. Oncol. 21 (1994) 613-619.
32. Labrie F., Dupont A., Cusan L., Gomez J. L. and Diamond P.: Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer. Clin. Invest. Med. 16 (1993) 493-498.
33. Labrie F., Cusan L., Gomez J. L., Diamond P., Suburu R., Lemay M., Têtu B., Fradet Y. and Candas B.: Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44 (1994) 29-37.